公开(公告)号：US20170296649A1

公开(公告)日：2017-10-19

申请号：US15326940

申请日：2015-07-17

申请人： Hiroshi KAWAMOTO

发明人： Hiroshi Kawamoto ,  Kyoko Masuda ,  Takuya Maeda ,  Seiji Nagano ,  Yoshimoto Katsura

IPC分类号： A61K39/245 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/5158 ,  A61K2039/585 ,  C12N7/00 ,  C12N2710/16234

摘要： Provided is a method for inducing T cells for a cell-based immunotherapy, which comprises the steps of: (1) providing human pluripotent stem cells bearing a T cell receptor specific for a desired antigen, and (2) inducing T cell progenitors or mature T cells from the pluripotent stem cells of step (1). Especially, a method for inducing T cells for a cell-based immunotherapy from cells of a person who is not the subject to be treated by the cell-based immunotherapy. The method provided herein may further comprise a step of co-culturing the T cell progenitors or mature T cells induced from the pluripotent stem cells with the lymphocytes of the subject to be treated by the cell based immunotherapy to verify that the T cells are not allogenicaly reactive against the subject.

公开(公告)号：US20170152479A1

公开(公告)日：2017-06-01

申请号：US15350124

申请日：2016-11-14

申请人： Immunicum AB

发明人： Alex Karlsson-Parra ,  Anna-Carin Wallgren ,  Bengt Andersson

IPC分类号： C12N5/0783 ,  A61K39/145 ,  A61K35/17

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/5158 ,  C12N2502/11 ,  C12N2502/1121 ,  C12N2710/16134 ,  C12N2710/16234 ,  C12N2760/16134

摘要： The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

公开(公告)号：US20170042998A1

公开(公告)日：2017-02-16

申请号：US15337415

申请日：2016-10-28

申请人： GENEIUS BIOTECHNOLOGY, INC.

发明人： ALFRED E. SLANETZ

IPC分类号： A61K39/00 ,  A61K39/245 ,  A61K39/29

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K9/0021 ,  A61K39/0008 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/245 ,  A61K39/292 ,  A61K2035/124 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/585 ,  C12N5/0636 ,  C12N7/00 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/999 ,  C12N2710/16034 ,  C12N2710/16234 ,  C12N2730/10134 ,  C12N2730/10171

摘要： The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.

公开(公告)号：US20150174237A1

公开(公告)日：2015-06-25

申请号：US14416780

申请日：2013-07-26

申请人： The Henry M. Jackson Foundation for the Advancement of military Medicine, Inc.

发明人： James J. Mond ,  Clifford M. Snapper ,  Xinle Cui

IPC分类号： A61K39/245 ,  C07K14/005

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/00 ,  C12N2710/16234 ,  C12N2740/15022 ,  C12N2740/15034 ,  Y02A50/386 ,  Y02A50/403 ,  Y02A50/478

摘要： The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizmg antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins, Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.

摘要翻译： 本公开提供融合蛋白，其掺入多重抗体抗原的独特机制以增强其免疫原性。 融合蛋白包含由接头序列和寡聚化结构域分开的至少两种抗原或其它疫苗相关蛋白。 当表达时，融合蛋白形成muKimeric蛋白复合物。该方法可用于单个抗原/蛋白质或产生包含两种或更多种不同抗原/蛋白质的多聚体。 还提供了编码融合蛋白的核酸。另一方面涉及通过向受试者施用包含融合蛋白或编码融合蛋白的核酸的疫苗组合物来诱导或抑制受试者的免疫应答的方法，任选地不使用 佐剂。

公开(公告)号：US20130064844A1

公开(公告)日：2013-03-14

申请号：US13591513

申请日：2012-08-22

申请人： Richard Spaete ,  Winthrop Jackman

发明人： Richard Spaete ,  Winthrop Jackman

IPC分类号： A61K39/245 ,  C12N1/19 ,  C12N1/21 ,  A61P31/22 ,  C12P21/02 ,  C12N15/38 ,  C07K14/05 ,  C12N15/63 ,  C12N5/10

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5555 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2710/16222 ,  C12N2710/16234

摘要： Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.

摘要翻译： 提供了包含gp350变体DNA和氨基酸序列的组合物，以及含有这种序列的载体和宿主细胞。 还提供了重组产生均匀的gp350蛋白并且在不产生gp220蛋白的过程中，含有这种蛋白质的药物组合物和使用这种蛋白质的预防性治疗。

公开(公告)号：US20120288520A1

公开(公告)日：2012-11-15

申请号：US13406153

申请日：2012-02-27

申请人： Konstantin V. Pugachev ,  Farshad Guirakhoo ,  Thomas P. Monath

发明人： Konstantin V. Pugachev ,  Farshad Guirakhoo ,  Thomas P. Monath

IPC分类号： C12N7/04 ,  C12N15/40 ,  A61P31/14 ,  A61K39/12

CPC分类号： C12N7/00 ,  C07K14/005 ,  C12N2710/16234 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24162 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/396

摘要： The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.

摘要翻译： 本发明提供可用于预防和治疗黄病毒感染的重组黄病毒疫苗。 本发明的疫苗含有重组黄病毒，包括减毒突变。

公开(公告)号：US20110287039A1

公开(公告)日：2011-11-24

申请号：US13090932

申请日：2011-04-20

申请人： IAN HECTOR FRAZER ,  JULIE LOUISE DUTTON

发明人： IAN HECTOR FRAZER ,  JULIE LOUISE DUTTON

IPC分类号： A61K39/00 ,  A61P31/00 ,  A61P33/00 ,  C07H21/04

CPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/95 ,  C12N15/85 ,  C12N2710/16234 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2760/16134 ,  C12N2770/24234 ,  C12N2840/102 ,  C12N2840/105 ,  C40B50/06

摘要： The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.

摘要翻译： 本发明公开了用于调节哺乳动物对靶抗原的免疫应答质量的方法和组合物，其响应来自编码至少一部分目标抗原的多核苷酸的表达，其中质量通过 所述多核苷酸的至少一个密码子具有同义词密码子，所述同义密码子具有比所替代的密码更高或更低的哺乳动物赋予免疫应答的优先权。

公开(公告)号：US20110236685A1

公开(公告)日：2011-09-29

申请号：US12912579

申请日：2010-10-26

申请人： Steve J.D. BELL ,  Tulin MORCOL ,  Qing HE

发明人： Steve J.D. BELL ,  Tulin MORCOL ,  Qing HE

IPC分类号： B32B5/16 ,  A61K39/00 ,  A61K9/00 ,  A61K9/14 ,  A61K9/12 ,  C01B25/32

CPC分类号： A61K39/39 ,  A61K9/0043 ,  A61K9/12 ,  A61K9/1611 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/5078 ,  A61K9/51 ,  A61K9/5115 ,  A61K36/064 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2013 ,  A61K38/208 ,  A61K38/28 ,  A61K39/04 ,  A61K39/12 ,  A61K39/145 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/55505 ,  A61K2039/55555 ,  C12N15/87 ,  C12N2710/16234 ,  C12N2710/16634 ,  C12N2740/16034 ,  C12N2760/16134 ,  Y10T428/2982

摘要： Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such as antigenic material or natural immunoenhancing factor, polynucleotide material, or therapeutic proteins or peptides, partially coating the particle or impregnated therein. The core particles have a diameter between about 300 nm and about 4000 nm, more particularly between about 300 nm and about 2000 nm, and even more particularly between about 300 nm and about 1000 nm, are substantially spherical in shape, and have a substantially smooth surface

摘要翻译： 公开了新型磷酸钙核心颗粒，其制备方法和使用它们作为疫苗佐剂的方法，作为核心，作为生物活性物质的载体，以及用作生物活性物质的控制释放基质。 核心颗粒可以具有表面改性剂和/或生物活性材料，例如部分包被颗粒或浸渍在其中的抗原材料或天然免疫增强因子，多核苷酸材料或治疗性蛋白质或肽。 核心颗粒的直径在约300nm至约4000nm之间，更特别地在约300nm至约2000nm之间，甚至更特别在约300nm至约1000nm之间，其形状基本上为球形，并且具有基本平滑的 表面

公开(公告)号：US20110059486A1

公开(公告)日：2011-03-10

申请号：US12716806

申请日：2010-03-03

申请人： Richard SPAETE ,  Winthrop JACKMAN

发明人： Richard SPAETE ,  Winthrop JACKMAN

IPC分类号： C12P21/06 ,  C12N5/10 ,  C12N15/63 ,  C07H21/04

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5555 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2710/16222 ,  C12N2710/16234

摘要： Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.

摘要翻译： 提供了包含gp350变体DNA和氨基酸序列的组合物，以及含有这种序列的载体和宿主细胞。 还提供了重组产生均匀的gp350蛋白并且在不产生gp220蛋白的过程中，含有这种蛋白质的药物组合物和使用这种蛋白质的预防性治疗。

公开(公告)号：US20110059133A1

公开(公告)日：2011-03-10

申请号：US12744474

申请日：2008-11-27

申请人： Dinesh Adhikary ,  Uta Behrends ,  Josef Mautner ,  Henri-Jacques Delecluse ,  Regina Feederle

发明人： Dinesh Adhikary ,  Uta Behrends ,  Josef Mautner ,  Henri-Jacques Delecluse ,  Regina Feederle

IPC分类号： A61K39/245 ,  C12N5/0783 ,  A61P37/04

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5158 ,  A61K2039/5258 ,  C12N5/0636 ,  C12N2502/11 ,  C12N2710/16234

摘要： The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.

摘要翻译： 本发明公开了一种用于制备含有EBV结构抗原特异性CD4 + T细胞的制剂的离体方法，用于预防和治疗T细胞活性降低的患者，以预防或治疗EBV感染的B细胞的生长。